Free press releases distribution network?

Agency / Source: Bio3 Research Srl

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Bio3 Research Srl and ProtElix, Inc. Enter into an Agreement for the Development of Mimic-antibody - Bio3 Research S.r.l. and ProtElix Inc. enter into an agreement for the development of mimic-antibody HMGB1 antagonists to prevent restenosis and atherosclerotic plaque progression - Bio3Research.com
Bio3 Research Srl and ProtElix, Inc. Enter into an Agreement for the Development of Mimic-antibody

 

PRZOOM - /newswire/ - Milano, Italy, 2008/09/17 - Bio3 Research S.r.l. and ProtElix Inc. enter into an agreement for the development of mimic-antibody HMGB1 antagonists to prevent restenosis and atherosclerotic plaque progression - Bio3Research.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Bio3 Research S.r.l. and ProtElix, Inc. announced today that they have entered into a non-exclusive worldwide collaboration for the development and commercial exploitation of mimic-antibody HMGB1 antagonists to prevent restenosis and atherosclerotic plaque progression. Anti-HMGB1 mimic-Abs will be generated by ProtElix using its proprietary technology platform and under a non-exclusive license to utilize Bio3 Research’s patent (IP WO02074437) relating to HMGB1 for cardiovascular disorders. Patents have been granted to Bio3 Research in Italy and Australia and the patent nationalization phase is underway in the USA, EU, Japan, Canada, China and Mexico.
Through a licensing program, Bio3 Research and ProtElix will jointly carry out the commercial exploitation of the mimic-Abs in key pharmaceutical markets. No details on commercial terms have been disclosed.

Dr Roberto Crea, Chairman and CEO of Protelix Inc., commented, “The collaboration with Bio3 Research is a great opportunity for ProtElix to direct its proprietary antibody mimics platform to important applications in cardiovascular diseases and cancer. We are very pleased to combine Bio3 Research’s Intellectual Property and marketing expertise with our “core” technology to discover and develop cheaper and more effective protein drug antagonists”.

Mr. Francesco Paolo Pilato, President and Chief Executive Officer of Bio3 Research commented: “Mimic-Abs represent an innovative approach to antagonizing HMGB1, a biological target recognized as one of the major factors contributing to several cardiovascular disorders. The world market potential for therapeutics in this area is in the range of $35 Billion. Bio3 Research has already focused on the possible development of monoclonal antibodies to antagonize HMGB1. By developing an HMGB1-specific mimic-antibody using ProtElix’s pioneering technology, we may accelerate the development of new therapeutic tools with better tissue penetration, the potential for non-injected formulations, higher stability, lower production costs and longer shelf-life.

ProtElix Inc. is a biotech R&D company located in Hayward, CA, USA. The Company was founded in 2006 by Dr. Roberto Crea, a serial entrepreneur in the biotech industry, as result of the sale of Bioren, Inc. to Pfizer in 2005. While Pfizer has acquired the worldwide exclusive rights to protein engineering technology for applications in the antibody space, ProtElix has retained the rights to the same platform technology for all other class of protein therapeutics. The Company has focused its initial technology applications on protein antagonists and enzyme engineering.

Bio3 Research S.r.l. is a biopharmaceutical company with its corporate headquarters in Milan, Italy and a subsidiary, Bio3 Research Inc., based in Hayward CA, USA. The company is engaged in several development projects, including the use of HMGB1 in connective tissue regeneration and the prevention of severe anemia in hemodialyzed patients with its proprietary therapeutic agent Biocysan™, already licensed to Daxley Group in Latin America and Mexico.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Bio3 Research Srl

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Bio3 Research Srl and ProtElix, Inc. Enter into an Agreement for the Development of Mimic-antibody

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Federico Gardini - Bio3Research.com 
f.gardini[.]bio3research.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Bio3 Research Srl securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Bio3 Research Srl / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  S&A Capital Partner Ltd

Visit  MagLar, Inc.

Visit  La Bella Bakery Artisan Bakery Arizona







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today